These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34536669)

  • 21. Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of γ-secretase activity.
    Song H; Chang YJ; Moon M; Park SK; Tran PT; Hoang VH; Lee J; Mook-Jung I
    J Alzheimers Dis; 2015; 43(3):797-807. PubMed ID: 25114069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
    Morawski M; Schilling S; Kreuzberger M; Waniek A; Jäger C; Koch B; Cynis H; Kehlen A; Arendt T; Hartlage-Rübsamen M; Demuth HU; Roßner S
    J Alzheimers Dis; 2014; 39(2):385-400. PubMed ID: 24164736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.
    Jawhar S; Wirths O; Schilling S; Graubner S; Demuth HU; Bayer TA
    J Biol Chem; 2011 Feb; 286(6):4454-60. PubMed ID: 21148560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template.
    Tran PT; Hoang VH; Thorat SA; Kim SE; Ann J; Chang YJ; Nam DW; Song H; Mook-Jung I; Lee J; Lee J
    Bioorg Med Chem; 2013 Jul; 21(13):3821-30. PubMed ID: 23643900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and Evaluation of a Novel PET Radioligand for Imaging Glutaminyl Cyclase Activity as a Biomarker for Detecting Alzheimer's Disease.
    Behof WJ; Haynes JR; Whitmore CA; Cheung YY; Tantawy MN; Peterson TE; Wijesinghe P; Matsubara JA; Pham W
    ACS Sens; 2024 May; 9(5):2605-2613. PubMed ID: 38718161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased glutaminyl cyclase activity in brains of Alzheimer's disease individuals.
    Gunn AP; Wong BX; McLean C; Fowler C; Barnard PJ; Duce JA; Roberts BR;
    J Neurochem; 2021 Mar; 156(6):979-987. PubMed ID: 32614980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
    Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
    Morawski M; Hartlage-Rübsamen M; Jäger C; Waniek A; Schilling S; Schwab C; McGeer PL; Arendt T; Demuth HU; Rossner S
    Acta Neuropathol; 2010 Aug; 120(2):195-207. PubMed ID: 20383514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A patent review of glutaminyl cyclase inhibitors (2004-present).
    Coimbra JRM; Salvador JAR
    Expert Opin Ther Pat; 2021 Sep; 31(9):809-836. PubMed ID: 33896339
    [No Abstract]   [Full Text] [Related]  

  • 30. Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer's Disease.
    Feldman HH; Messer K; Qiu Y; Sabbagh M; Galasko D; Turner RS; Lopez O; Smith A; Durant J; Lupo JL; Revta C; Balasubramanian A; Kuehn-Wache K; Wassmann T; Schell-Mader S; Jacobs DM; Salmon DP; Léger G; DeMarco ML; Weber F;
    J Alzheimers Dis; 2024; 101(s1):S79-S93. PubMed ID: 39422941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacophore-driven identification of human glutaminyl cyclase inhibitors from foods, plants and herbs unveils the bioactive property and potential of Azaleatin in the treatment of Alzheimer's disease.
    Tsai KC; Zhang YX; Kao HY; Fung KM; Tseng TS
    Food Funct; 2022 Dec; 13(24):12632-12647. PubMed ID: 36416361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
    Ramsbeck D; Buchholz M; Koch B; Böhme L; Hoffmann T; Demuth HU; Heiser U
    J Med Chem; 2013 Sep; 56(17):6613-25. PubMed ID: 23886302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl)phenyl]benzimidazoles.
    Ozadali-Sari K; Tüylü Küçükkılınç T; Ayazgok B; Balkan A; Unsal-Tan O
    Bioorg Chem; 2017 Jun; 72():208-214. PubMed ID: 28478328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benzimidazole-derived Compounds Designed for Different Targets of Alzheimer's Disease.
    Gulcan HO; Mavideniz A; Sahin MF; Orhan IE
    Curr Med Chem; 2019; 26(18):3260-3278. PubMed ID: 30678614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
    Bridel C; Hoffmann T; Meyer A; Durieux S; Koel-Simmelink MA; Orth M; Scheltens P; Lues I; Teunissen CE
    Alzheimers Res Ther; 2017 Jun; 9(1):38. PubMed ID: 28587659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease.
    Gutti G; Kakarla R; Kumar D; Beohar M; Ganeshpurkar A; Kumar A; Krishnamurthy S; Singh SK
    Eur J Med Chem; 2019 Nov; 182():111613. PubMed ID: 31437780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying hQC Inhibitors of Alzheimer's Disease by Effective Customized Pharmacophore-Based Virtual Screening, Molecular Dynamic Simulation, and Binding Free Energy Analysis.
    Lin W; Zheng X; Fang D; Zhou S; Wu W; Zheng K
    Appl Biochem Biotechnol; 2019 Apr; 187(4):1173-1192. PubMed ID: 30187344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice.
    Wang X; Wang L; Yu X; Li Y; Liu Z; Zou Y; Zheng Y; He Z; Wu H
    Int Immunopharmacol; 2019 Oct; 75():105770. PubMed ID: 31377588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders.
    Pozzi C; Di Pisa F; Benvenuti M; Mangani S
    J Biol Inorg Chem; 2018 Dec; 23(8):1219-1226. PubMed ID: 30132075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.